Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective lead-in observational study of bleeding and FVIII use in adults with hemophilia A
2019-004480-48Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Factor VIII in hemophilia A, sponsored by Bayer. Primary endpoint: Annualized bleeding rate (all bleeds). Started Jun 2021; status: terminated.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2019-004480-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004480-48.